title: Potassium-sparing diuretics.
abstract: The hemodynamic and the endocrine disturbances in congestive heart failure (CHF) impose major changes in electrolyte balance with a retention of sodium and concomitant losses of potassium and magnesium from the body. These changes are of great importance for the development of cardiac dysrhythmias, a diminished glucose tolerance and for the well-being of the patient. The use of conventional diuretics imposes further burdens on the already deranged electrolyte balance. On long-term therapy with conventional diuretics in CHF we observed that approximately 50% of the 297 patients studied had potassium and magnesium deficiencies and an increased sodium content as judged by skeletal muscle biopsies. The magnesium deficiency is especially dangerous since it prevents the cells from keeping their high intracellular potassium concentration unchanged. Potassium substitution is without effect in a magnesium deficiency since magnesium is necessary for the transportation of potassium over the cell membrane against the concentration gradient. In case of magnesium depletion, potassium substitution may even have negative effects on the body potassium content. The reason for this is probably the increase of p-potassium concentration induced by the substitution, leading to an increase of aldosterone secretion. An increase of p-potassium levels by 0.2-0.4 mmol/l may thus result in a 50-100% rise in p-aldosterone concentration. These changes promote further urinary losses of potassium and magnesium. Several studies have demonstrated the positive effects of the potassium-sparing diuretics amiloride, spironolactone and triamterene on p-potassium concentration, but also on the body potassium content.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: T
authors.initials: T
authors.lastname: Dyckner
authors.forename: P O
authors.initials: PO
authors.lastname: Wester
mesh_terms: D000584:Amiloride / Q000627:therapeutic use; D004232:Diuretics / Q000494:pharmacology / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007008:Hypokalemia / Q000378:metabolism; D008275:Magnesium Deficiency / Q000378:metabolism; D011188:Potassium / Q000378:metabolism*; D013148:Spironolactone / Q000627:therapeutic use; D014223:Triamterene / Q000627:therapeutic use; D014883:Water-Electrolyte Imbalance / Q000378:metabolism
chemical_list: D004232:Diuretics; D013148:Spironolactone; D000584:Amiloride; D011188:Potassium; D014223:Triamterene